CTI Life Sciences

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Find Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare inflammatory and fibrotic diseases affecting the airways, liver, and gastrointestinal systems. Founded in 2020 and headquartered in Saint-Laurent, Canada, the company specializes in creating G protein-coupled receptor (GPCR) allosteric modulators and employs a peptide discovery engine to design peptide-based therapies. These therapies target transmembrane domains of receptors that play crucial roles in various biological processes, facilitating the development of next-generation treatments for autoimmune conditions. By leveraging advanced technology and research capabilities, Find Therapeutics aims to address unmet medical needs in the field of inflammatory diseases.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Find Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare inflammatory and fibrotic diseases affecting the airways, liver, and gastrointestinal systems. Founded in 2020 and headquartered in Saint-Laurent, Canada, the company specializes in creating G protein-coupled receptor (GPCR) allosteric modulators and employs a peptide discovery engine to design peptide-based therapies. These therapies target transmembrane domains of receptors that play crucial roles in various biological processes, facilitating the development of next-generation treatments for autoimmune conditions. By leveraging advanced technology and research capabilities, Find Therapeutics aims to address unmet medical needs in the field of inflammatory diseases.

PreciThera is a biotechnology company dedicated to developing targeted therapies for rare bone diseases. It focuses on heterogeneous genetic disorders that primarily affect bone function, utilizing computational technology and a deep understanding of disease pathology to address both skeletal symptoms and extraskeletal issues.

Ilkos Therapeutic is a company focused on developing an oral compound specifically designed to treat venous lower limb ulcers, a condition primarily affecting older adults. The firm capitalizes on Quebec's strong life sciences sector, leveraging its quality research and development infrastructure alongside available capital to advance new therapeutic solutions. By providing an effective treatment option for this challenging medical issue, Ilkos Therapeutic aims to enhance patient care and improve outcomes for those suffering from venous lower limb ulcers.

Medicago Inc. is a biotechnology company headquartered in Quebec City, Canada, specializing in the research, development, and commercialization of vaccines. The company employs proprietary plant-based manufacturing and virus-like particle (VLP) technologies to create innovative vaccines and therapeutics for infectious diseases. Its notable product candidates include a VLP vaccine for the H5N1 pandemic influenza, which has successfully completed Phase I clinical trials, as well as an H1N1 VLP vaccine aimed at the Influenza A/California/04/09 virus and various seasonal influenza vaccines. Medicago has established collaboration agreements with organizations such as Viridis S.A. and Genopole biopark for the production of pandemic and seasonal influenza vaccines, alongside a partnership with Philip Morris International for developing a therapeutic protein with a human-compatible glycosylation pattern. Founded in 1997, Medicago is dedicated to addressing emerging public health challenges through its advanced vaccine technologies.